
    
      The study will include a screening period of up to 21 days (Day -21 to -1), a study treatment
      period [Day 1 to Day 57 for Acute Lymphoblastic Leukemia (ALL); Day 1 to Day 22 for Acute
      Myeloid Leukemia (AML)], a recovery period (until an end of treatment visit [within 30 days
      after hematological recovery]) and a follow-up period (until final analysis cut off date).
    
  